raloxifene hydrochloride has been researched along with Bladder Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bjorling, DE; Keil, KP; Moses, MA; Nicholson, TM; Ricke, WA; Uchtmann, KS; Vezina, CM; Wood, RW | 1 |
1 other study(ies) available for raloxifene hydrochloride and Bladder Diseases
| Article | Year |
|---|---|
Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia.
Topics: Animals; Estrogen Receptor alpha; Estrogen Receptor beta; Male; Mice; Mice, Inbred C57BL; Prostatic Hyperplasia; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Urinary Bladder Diseases | 2015 |